|Name of the organisation||Person of contact||Country|
|3D PLUS SAS||Pascal Couderc||France|
|AlveoliX AG||Olivier Guenat, Nina Hobi, Janick Stucki||Switzerland|
|Axe PI||Axel Gerhardt|
|Bayer AG||Lars Küpfer||Germany|
|Bioanalytic Münster||Klaus-Michael Weltring||Germany|
|Biocam Scarl||Lucio Annunziato||Italy|
|Biovista||Andreas Persidis, Eftychia Lekka||Greece|
|Bosch BKK||Franz Laermer||Germany|
|Bracco Imaging s.p.a.||Fulvio Uggeri||Italy|
|CEDEO SAS||Leonardo Chiariglione||Italy|
|Centre for Process Innovation||Charanjeet Singh||United Kingdom|
|Copenhagen Center for Health Technology (cachet)||Jakob E. Bardram, Professor and Director||Denmark|
|Corti||Michael R. Boesen, PhD, Co-founder and VP Special Projects||Denmark|
|CPH Health CHC||Henning Langberg||Denmark|
|Cyprus Chamber of Commerce and Industry||Leonidas Paschalides||Cyprus|
|Cyprus Ministry of Health||Christina Yiannaki||Cyprus|
|DDS Diagnostic||Dana Stan||Romania|
|Diavita Ltd||Dimiter Dimitrov||Bulgaria|
|Dr. Schär||Ombretta Polenghi||Italy|
|Dutch Heart Foundation||Rebecca Abma-Schouten||The Netherlands|
|Edinethics Ltd||Donald Bruce||United Kingdom|
|EGAN||Cees Smit, Cor Oosterwijk||The Netherlands|
|Eriksholm Research Center (part of Oticon)||Uwe Hermann, Director||Denmark|
|European Federation of Neurological Associations (EFNA)||Cathalijne van Doorne||Belgium|
|European Federation of Pharmaceutical Industries and Associations (EFPIA)||Magda Chlebus||Belgium|
|European Lung Foundation (ELF)||Emma Thompson, Isabel Sairava||United Kingdom|
|European Society for Biomaterials ESB||Pamela Habibovic||France|
|F.R.S.-FNRS Fonds de la Recherche Scientifique||Véronique Halloin||Belgium|
|Fonds de recherche du Québec||Rémi Quirion||Canada|
|Genomics Canada||Marc Lepage||Canada|
|GenomSys SA||Claudio Alberti||Switzerland|
|greenTEG AG||Wulf Glatz||Switzerland|
|Génome Québec||Daniel Coderre||Canada|
|Hauptverband der österreichischen Sozialversicherungsträger||Alexander Biach||Austria|
|Health Insurance Organisation||Athos Tsinontides||Cyprus|
|Helmholtz Inst for Pharma science||Claus-Michael Lehr||Germany|
|INRA - Human Nutrition Unit||Sergio Polakof, Estelle Pujos-Guillot||France|
|InSphero AG||Olivier Frey, Jan Lichtenberg||Switzerland|
|Institute for Clinical Pharmacology (IKP)||Matthias Schwab||Germany|
|Intelligent Voice Ltd||France||Gérard Chollet|
|IST AG||Mirko Lehmann||Switzerland|
|Istituto Superiore di Sanità||Giovanna Schiavoni||Italy|
|Janssen||Rachel Adams||United Kingdom|
|liferesult srl||Massimo Pistoia||Italy|
|LioniX International BV||Henk Leeuwis||The Netherlands|
|MaxWell Biosystems||Urs Frey, Michele Fiscella||Switzerland|
|Medicines Evaluation Board (the Netherlands)||Jan Willem van der Laan||The Netherlands|
|Melanoma Patient Network Europe||Bettina Ryll||Belgium|
|Merck KGaA (Ares Trading SA)||Charles Massin||Switzerland|
|Micronit||Ronny van 't Oever||The Netherlands|
|Microsoft Denmark||Kim Ibfelt||Denmark|
|Mila - Quebec Articifcial Intelligence Institute||Valérie Pisane||Canada|
|Military Hospital Brussels||Vanhoutte||Belgium|
|MinacNed||Ronny van ‘t Oever||The Netherlands|
|Mobile Health Unit||Valerie Storms||Belgium|
|National Research Council Canada||Jean-François Houle||Canada|
|NC3Rs||Sam Jackson||United Kingdom|
|Neurescue||Habib Frost, Founder and CEO||Denmark|
|NXP Semiconductors||Radu Surdeanu||The Netherlands|
|Ontario Genomics||Bettina Hamelin||Canada|
|Pfizer||Mark Soued||The Netherlands|
|Philips Electronics Nedeland B.V.||Sieger Swaving||The Netherlands|
|Photonics 21||Jürgen Popp, Thomas Mayerhoefer||Germany|
|Polytechnique Montréal||François Bertrand||Canada|
|Praxis Pharmaceutical||Eusebio Gainza||Spain|
|Praxis Pharmaceutical (Keralty)||Eusebio Gainza||Latin America|
|Pryv SA||Hubert Ridolphi||Switzerland|
|Robert Bosch GmbH||Jürgen Gross||Germany|
|Roland Berger GmbH||Steffen Gackstatter||Germany|
|S.C. Telemedica S.R L||Mioara Radu||Romania|
|ST Microelectronics||G. Desoli, Rolandi Canegallo, A. Cremonesi, Sabina Conoci||Italy|
|Syndicat National de l’Industrie des Technologies Médicales (SNITEM)||Florent Surugue||France|
|Texas Instruments||Giovanni Frattini||United States|
|Tissue Click Ltd||Gary Phillips, Anna Guildford||United Kingdom|
|Université de Sherbrooke||Vincent Aimez||Canada|
|Vector Institute for Artificial Intelligence||Garth Gibson||Canada|
|VITO||Bart Van Meerbergen||Belgium|
|Wageningen - Food & Biobased Research||Jurriaan Mes, Liesbeth Luijendijk, Jan Top, Harry Wichers||The Netherlands|
|Wyss Center for Bio and Neuroengineering||Tracy Laabs||Switzerland|
|Zilveren Kruis Achmea||Anja Moonen||The Netherlands|
Patrick Boisseau, Deputy Head of Division, European Affairs at CEA-LETI and member of the Health EU steering board, presented the Health EU Flagship approach today at the CEO Summit 2018 in Brussels. The audience composed of 60+ industrial leaders in medtech and diagnostics companies was delighted about this foresight looking lecture. Some interesting questions about ethical and societal issues related to avatars or “when will it be available” gave rise for discussion and some very positive feedback was received during the coffee breaks.
Patrick Boisseau, Deputy Head of Division, European Affairs at CEA-LETI and Chairman of the ETPN, presented Health EU Flagship approach at ETPN 2018, Berlin, Germany, in a talk entitled: ''Human avatars to prevent and cure diseases Health EU vision for a sustainable future of the European healthcare'', attracting significant support and high interest from the audience for the Health EU Flagship.
Both of the EPFL projects that applied for the European Commission’s FET Flagship programme have successfully cleared the first hurdle. These projects are the Time Machine, headed by Frédéric Kaplan at the Digital Humanities Laboratory, and Health EU, run by Adrian Ionescu at the Nanoelectronic Devices Laboratory (Nanolab). If selected, they will receive one billion euros over ten years as part of the European Commission’s ambitious funding programme.
With Health EU, everyone will one day have their own medical avatar – a virtual replica of themselves featuring their own personal data – that could improve the way their health is managed and the treatments they are given. This international project, led by a consortium headed by EPFL and the University of Twente, aims to achieve enhanced disease prevention, early diagnosis, more accurate monitoring and customized, targeted administration of medicines and treatments, especially for increasingly common diseases such as cancer and cardiovascular, chronic and neurodegenerative disorders.
The Time Machine is based on the Venice Time Machine (VTM), a project that started in 2012 and served as a proof of concept. The VTM aimed to build a multidimensional model of the city that spans the past millennium, using millions of historical documents stored in a variety of formats. After five years, the project team has scanned 190,000 records from the Venice State Archive along with 720,000 photographs and 3,000 books on Venice’s history. The objective of the Time Machine is to replicate the VTM across Europe. It will create a large-scale simulator for mapping 2,000 years of European history and turning the huge archives and sizeable museum collections into one big digital information system.
A total of 33 projects from universities across Europe have applied for the programme, which is intended to support future and emerging technologies (FET). Only 17 of them – just over half – were selected for the second round, scheduled to end on 18 September 2018.EPFL also plays a key role in a third project in the running for a FET Flagship, Robotics Flagship, which made it through to the second round as well.
The full EPFL press release including more information about the proposals you can find here.
Professor Ben Feringa, who won the 2016 Nobel Prize in chemistry for the development of molecular machines, expresses his appreciation of the Health EU proposal: “This is a very ambitious programme that combines modern science and technology to create new opportunities for the future of healthcare and keep it affordable.”
Professor Feringa is a pioneer in the field of molecular engines, catalysis and smart medication.
Excellent news: The European Commission has invited the Health EU proposal to enter the next stage of competition for the selection of new EU Flagships for Future and Emerging Technologies.
We are thrilled to be one step closer to the realisation of our dream: a revolution in personalized healthcare and disease prevention system in Europe, based on human avatars of healthy individuals and patients for the prevention, interception and cure of disease.
The Health EU coordinating organisation, Ecole polytechnique fédérale de Lausanne (EPFL) has published today a press release presenting the project. Enjoy reading!
The Health EU phase 1 proposal has been submitted successfully yesterday!
It is one of 33 proposals submitted to the topic FETFLAG-01-2018: Preparatory Actions for new FET Flagships.
The results for phase 1 of the evaluation should be known in 3 months from now.